Efficacy of once daily bisoprolol in stable angina pectoris: an objective comparison with atenolol and long term follow-up
- PMID: 2866960
- DOI: 10.1093/oxfordjournals.eurheartj.a061771
Efficacy of once daily bisoprolol in stable angina pectoris: an objective comparison with atenolol and long term follow-up
Abstract
Bisoprolol is a new cardioselective beta-blocker with a long half-life. The efficacy of once daily bisoprolol (10 mg) and atenolol (100 mg) was assessed in 20 patients with stable angina using a placebo controlled double-blind randomized crossover protocol. Efficacy was assessed by computer assisted treadmill exercise testing with monitoring of leads CM5 and CC5, carried out 22-24 h after the last dose. The mean +/- SEM exercise time on placebo was 6.5 +/- 0.4 min increasing to 7.8 +/- 0.5 min on bisoprolol (P less than 0.001) and 8.6 +/- 0.6 mins on atenolol (P less than 0.001). The time to 1 mm ST depression in CM5 and CC5 was also prolonged significantly with both drugs. The mean basal resting heart rate of 84 +/- 4 bpm decreased to 63 +/- 2 bpm on bisoprolol (P less than 0.001) and 64 +/- 3 bpm on atenolol (P less than 0.001), with a significant decrease in the peak exercise heart rate seen with both drugs (P less than 0.001). The peak rate-pressure product was 175 +/- 8 after placebo, 146 +/- 7 (P less than 0.001) with bisoprolol and 149 +/- 5 (P less than 0.001) after atenolol. One patient was withdrawn because he suffered a myocardial infarction. Eighteen patients were prescribed bisoprolol 10 mg once a day for 6 weeks and an exercise test was performed at the end of this period. Bisoprolol retained its efficacy at the end of this period and was well tolerated.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Management of chronic stable angina with once-daily bisoprolol or atenolol and long-term efficacy of bisoprolol.J Cardiovasc Pharmacol. 1986;8 Suppl 11:S148-53. doi: 10.1097/00005344-198511001-00027. J Cardiovasc Pharmacol. 1986. PMID: 2439787 Clinical Trial.
-
A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris.Eur Heart J. 1987 Dec;8 Suppl M:37-42. doi: 10.1093/eurheartj/8.suppl_m.37. Eur Heart J. 1987. PMID: 2967184 Clinical Trial.
-
Comparison of bevantolol and atenolol in chronic stable angina.Am J Cardiol. 1988 Jun 1;61(15):1204-9. doi: 10.1016/0002-9149(88)91155-1. Am J Cardiol. 1988. PMID: 2897780 Clinical Trial.
-
Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.Drugs. 1988 Sep;36(3):256-85. doi: 10.2165/00003495-198836030-00002. Drugs. 1988. PMID: 2903820 Review.
-
Celiprolol in angina pectoris.Am Heart J. 1988 Nov;116(5 Pt 2):1422-5. doi: 10.1016/0002-8703(88)90134-2. Am Heart J. 1988. PMID: 2903653 Review.
Cited by
-
Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.Br J Clin Pharmacol. 1986 Sep;22(3):293-300. doi: 10.1111/j.1365-2125.1986.tb02890.x. Br J Clin Pharmacol. 1986. PMID: 2876722 Free PMC article. Clinical Trial.
-
Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.Cardiovasc Drugs Ther. 2022 Oct;36(5):959-971. doi: 10.1007/s10557-021-07205-y. Epub 2021 Jun 9. Cardiovasc Drugs Ther. 2022. PMID: 34106365 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical